Vericel Corp

+0.71 (+1.23%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)2.71B
Current PE944.63
Forward PE 533.55
2yr Forward PE 119.78
See more stats
Estimates Current Quarter
Revenue$32.04 Million
Adjusted EPS-$0.04
See more estimates
10-Day MAN/A
50-Day MAN/A
200-Day MAN/A
See more pivots

Vericel Corp. Stock, NASDAQ:VCEL

64 Sidney Street, Cambridge, Massachusetts 02139
United States of America
Phone: +1.800.556.0311
Number of Employees: 241


Vericel Corp. engages in the research, product development, manufacture, and distribution of patient-specific, expanded cellular therapies for use in the treatment of patients with diseases. Its product portfolio includes MACI and Epicel. The MACI portfolio is FDA-approved product that applies the process of tissue engineering to grow cells on scaffolds using healthy cartilage tissue from the patient's own knee. The Epicel portfolio provide skin replacement for patients who have deep dermal or full thickness burns. The company was founded on March 24, 1989 and is headquartered in Cambridge, MA.